Companies: 10,795·Total market cap: $144.5T
Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated

PRLDNASDAQHealthcare● Active
$3.84
+$0.03(+0.79%)
Market Cap$218621864
P/E Ratio—
52W High$5.54
52W Low$0.75
Overview

Prelude Therapeutics Incorporated (PRLD) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

prld · stock forecast · 8 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 8 Wall Street analysts in the past 3 months

SellBuy

Buy

8 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
5
Hold
1
Sell
2
Strong Sell
0
Total: 8 · Buy rate: 62.5%

12-Month Price Target

High

$8.00

Consensus

$8.00

+108.3% upside

Low

$8.00

Median: $8 · Last Close: $3.84

The Prelude Therapeutics Incorporated (PRLD) analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month PRLD price target is $8.00, representing +108.3% upside from the current price of $3.84.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Analyst price target coverage is insufficient to generate a forecast chart for this stock.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$3.65↓ 5.00%

1-day model range: $3.54–$3.75. Peak: $3.75 (-5.00%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)39.2
MACDBEARISH

Moving Averages · PRLD · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$3.78BUY
MA 10$3.88SELL
MA 20$4.18SELL
MA 50$4.28SELL
MA 100$3.44BUY
MA 200$0.00NEUTRAL
Current $PRLD · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$3.85SELL
EMA 10$3.93SELL
EMA 20$4.09SELL
EMA 50$4.04SELL
EMA 100$3.53BUY
EMA 200$0.00NEUTRAL
Current $PRLD · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-04-27
Maintains
Buy→Buy
Citizens2026-03-11
Maintains
Market Outperform→Market Outperform
HC Wainwright & Co.2025-09-23
Maintains
Buy→Buy
JMP Securities2025-08-18
Maintains
Market Outperform→Market Outperform
HC Wainwright & Co.2025-05-05
Maintains
Buy→Buy
JMP Securities2025-04-29
Maintains
Market Outperform→Market Outperform
HC Wainwright & Co.2025-04-08
Maintains
Buy→Buy
Citizens Capital Markets2025-03-12
Maintains
Market Outperform→Market Outperform
JMP Securities2024-12-11
Maintains
Market Outperform→Market Outperform
HC Wainwright & Co.2024-11-08
Maintains
Buy→Buy

Wall Street analysts have recently issued updated ratings on Prelude Therapeutics Incorporated (PRLD) stock. Of the recent 41 rating actions, 3 were upgrades and 6 were downgrades. 8 analysts currently cover PRLD.

Analyst Recommendation Trends

Buy ratings2 → 1↓ 1
Hold ratings0 → 0
Sell ratings0 → 0

PRLD analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$28M

↓ 78.3% YoY

Revenue Next Year

$53M

↑ 87.5% YoY

EPS This Year

$-0.65

EPS Next Year

$-0.61

↓ 4.9% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PRLD EPS of $-0.65 for the current fiscal year, based on estimates from 2 analysts. The PRLD revenue forecast is $28M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PRLD stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PRLD price target is $8.00 (+108.3% upside), with an analyst consensus of Buy.

The PRLD short-term stock prediction for tomorrow is $3.65 (-5.00%).

Prelude Therapeutics Incorporated trades on NASDAQ under the ticker PRLD. The PRLD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Related pages

EarningsRevenuePE RatioFinancialsMarket CapInsider TradesDividendsPrice History

Frequently asked questions

PRLD forecast · 8 questions

According to 8 Wall Street analysts, the average 12-month PRLD price target is $8.00, with a high forecast of $8.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies +108.3% potential upside from the current price of $3.84.

PRLD price targetWhat is PRLD price targetPRLD analyst price targetPRLD 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.